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A B S T R A C TIn the context of reemerging universalistic approaches to health care,
the objective of this article was to contribute to the discussion by
highlighting the potential influence of global trade liberalization on
the balance between health demand and the capacity of health
systems pursuing universal health coverage (UHC) to supply adequate
health care. Being identified as a defining feature of globalization
affecting health, trade liberalization is analyzed as a complex and
multidimensional influence on the implementation of UHC. The
analysis adopts a systems-thinking approach and refers to the six
building blocks of World Health Organization’s current ‘‘framework for
action,’’ emphasizing their interconnectedness.
While offering new opportunities to increase access to health
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ent, Bocconi University, via Roentgen 1, 20136 Miensuring adequate health protection and promotion, global trade tends
to have negative effects on health systems’ capacity to ensure UHC,
both by causing higher demand and by interfering with the intercon-
nected functioning of health systems’ building blocks. The prevention
of such an impact and the effective implementation of UHC would
highly benefit from a more consistent commitment and stronger
leadership by the World Health Organization in protecting health in
global policymaking fora in all sectors.
Keywords: global health governance, globalization, health systems,
trade, universal health coverage.
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In the context of reemerging universalistic approaches to health
care [1,2], this article contributes to the discussion by high-
lighting the influence of global forces on the balance between
health demand and the capacity of health systems pursuing
universal health coverage (UHC) to supply adequate health care.
Increased trade and trade liberalization is a defining feature of
globalization, directly and indirectly affecting health and health
systems. Understanding how trade liberalization affects a coun-
try’s health system and policy has been indicated as one of the
complex tasks in the stewardship of a domestic health system in
the 21st century [3]. Thus, global trade liberalization is analyzed
in this article as policy that also affects the implementation of
UHC, that is, ensuring accessible and affordable health services
appropriate to the needs of all individuals within a population [4].
Until recently, the effect of trade policies on health has been
studied mostly in relation to issues such as intellectual property
rights and trade in health services [5]. Social vulnerabilities,
however, interfere with the universality of UHC [6], and thus to
know how global trade contributes to poor health translating into
health care needs is equally paramount. Nevertheless, this aspect
has only recently received attention, with studies beginning todocument the impact of trade liberalization on social determi-
nants of health [7].
To study the complex and multidimensional impact of global
trade on a health system’s capacity to respond to populations’
health care needs, promoting or hindering the path toward UHC,
a systems-thinking approach is suggested [8]. Following this
approach, reference is made to the six building blocks of World
Health Organization’s (WHO’s) ‘‘framework for action’’—service
delivery; health workforce; information; medical products, vac-
cines, and technologies; financing; and leadership governance
[9]—emphasizing their interconnectedness.
In the following sections, the potential adverse effects of trade
on health demand are identified, followed by an overview of how
trade interacts with each of the building blocks of health systems.
The four modes of service delivery described by the General
Agreement on Trade in Services of the World Trade Organization
(WTO) are used for this purpose: mode 1 or cross-border supply
(e.g., the provision of diagnosis or treatment planning services in
country A by suppliers in country B, via ‘‘telemedicine’’); mode 2 or
consumption abroad (e.g., movement of patients from country A to
country B for treatment); mode 3 or commercial presence (e.g.,
establishment of or investment in hospitals in country A whose
owners are from country B); and mode 4 or presence of naturalSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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who are nationals of country B) [10].
Finally, the limited scope of current global health governance
arrangements is highlighted, asserting that the effective imple-
mentation of UHC will benefit highly from a more consistent
commitment and stronger leadership by the WHO in protecting
health in global policymaking fora in all sectors.Trade Influence on Health Needs and Demand
A number of recent studies and empirical investigations infer a
robust association between the process of globalization domi-
nated by neoliberal economic ideas and policies of privatization,
deregulation, and liberalization, and unsatisfactory health trends
[11,12]. Trade can affect health outcomes via a very diverse
number of direct and indirect pathways. Among them, income
and its distribution, income inequality, economic insecurity, and
unhealthy lifestyles link trade policy to social determinants of
health and, often negative, health outcomes [5]. The following are
a few examples of this complex interaction.
Trade is directly associated with the adoption of unhealthy
‘‘Western lifestyles’’ and a worldwide increase in chronic dis-
eases, with a heavier burden for poorer countries. The global food
industry has a direct role in the nutritional transition toward
high-energy dense diets leading to the current obesity pandemic,
and the growing burden and high mortality deriving from related
chronic diseases [13]. The latter are equally associated with the
tobacco industry and its aggressive marketing strategies, taking
special advantage of the potential for growth in developing
countries and pushing for increased consumption among already
vulnerable population groups. Trade in alcohol follows similar
patterns [14].
Hazardous wastes are globally traded and disposed in low-
income countries, with highest exposure to the poorest popula-
tions [15]. The dominant development model, based on uncon-
trolled economic growth thriving on sustained consumption and
waste, besides being unsustainable, produces increasing envir-
onmental degradation [16]. The result has been a steady increase
in chronic diseases, and in some cases with irreversible transge-
nerational epigenetic change (i.e., changes in the genome activity
that take place without modifying the DNA sequence, but may be
transmitted to the progeny) [17]. In addition, related climatic
changes have additional negative health outcomes, with the
possibility of catastrophic epidemiological transformation [18].
The effects of privatization and trade of water promoted by
international financial institutions is also the object of increasing
concern in terms of reduced water security and water-related
diseases [14].
Trade and investment treaties increasingly limit the policy
space for public regulatory interventions to protect public health.
International trade agreements are scarcely influenced by health
concerns and may in fact prevent countries from regulating the
import of health-damaging products (e.g., tobacco, alcohol, and
unhealthy foods). Such measures are likely to be seen as trade
restrictive under these agreements, which are managed under a
highly structured and demanding governance system. In con-
trast, the global health governance domain exhibits little struc-
tural coherence, a greater diversity of actors, and weaker legal
obligations on states [19,20].
Nevertheless, public health–oriented regulatory processes are
possible and have been shown to be fundamental in limiting the
trade and use of harmful substances. The Framework Convention
on Tobacco Control led by the WHO is possibly the best example
of how this agency can exercise its mandate for health through
internationally binding instruments. Even international nonbind-
ing ‘‘soft law’’ can limit commercial practices affecting health, asin the case of the WHO-UNICEF international code of marketing
of breast milk substitutes, or recommendations concerning the
formulation, nutritional labeling, and marketing of processed
food [5,21].Trade Influence on Health System’s Building Blocks
Trade’s interaction with health systems’ supply capacity is use-
fully described by mapping WTO’s four modes of trade in health
services onto each of WHO’s six ‘‘building blocks’’: service delivery;
health workforce; information; medical products, vaccines, and
technologies; financing; and leadership governance [9]. The inter-
dependence and the multidimensional nature of the interaction
between these blocks must, however, be kept in mind.
Service Delivery
Health services are tradable commodities under the WTO and
other regional and bilateral agreements. Health is increasingly
perceived as a private good at the mercy of the law of the market.
The provision of health care through market relationships,
investment in and production of services for profit, and health
care finance by individual payment and private insurance, that is,
‘‘commercialized’’ health care [22], may increase the consumers’
choice, but long-term dangers have been shown—such as estab-
lishing a two-tier health system, movement of health workers
from the public sector to the private sector, and inequitable
access to health care [14].
Opening up domestic markets to foreign direct investment
(i.e., WTO ‘‘mode 3’’) and commercialized health care have been
promoted by economic pressures and international policies since
the 1980s, mainly through health sector reforms associated with
macroeconomic structural adjustment programs imposed on
indebted countries by the international financial institutions
and donors. This has been accompanied by the dismantling of
relatively equitable systems for social and economic provision
[15]. Out-of-pocket payments, one of the most poverty-inducing
forms of health finance, often became the rule in low-income
countries. A comprehensive study conducted by the United
Nations Research Institute for Social Development in 20 devel-
oping and transitional countries between 2003 and 2005 showed
that unregulated commercialized health systems were highly
inefficient and costly; they exacerbated inequality and provided
poor quality, and at times, dangerous, care. Commercialization of
primary care was also associated with the exclusion of children
from both curative and preventive care [1,22].
Through ‘‘health tourism’’ (e.g., WTO ‘‘mode 2’’—consumption
of services abroad), an increasing flow of patients use elective
health services in foreign countries, eventually in search of
services unavailable or unaffordable in their country. Health
tourism can promote the economic growth of destination coun-
tries and, potentially, reduce the emigration of their health
workers in search of better opportunities. But by incentivizing
the movement of health workers from rural to urban settings,
and from public to private health care facilities catering
to foreign consumers, private health care provision to ‘‘health
tourists’’ can also worsen national residents’ access to health
services, especially of poorer groups less able to afford private
care [20]. There are clear interlinkages between cross-border
delivery of services through telehealth services (i.e., WTO ‘‘mode
1’’) and WHO’s ‘‘information’’-building block. These interlinkages
are reviewed below.
Health Workforce
The WHO estimates a worldwide shortage of 4.3 million health
workers; this constitutes a major barrier in many countries to the
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health personnel by wealthy destination countries is an impor-
tant ‘‘pull factor’’ for the outflow of thousands of health workers
from poorer and disadvantaged countries [23].
Trade via the international movement of health service
providers (i.e., WTO ‘‘mode 4’’) can generate remittances, con-
tribute to the exchange of knowledge among professionals, and
provide countries of destination with otherwise unavailable
skills. The permanent emigration of health professionals may
exacerbate health worker shortages in source countries, thus
hampering adequate service delivery. Already fragile health
systems are further weakened, while public resources invested
in their training are lost [24].
In 2010, the 63rd World Health Assembly acknowledged the
global dimension and complexity of the health workforce crisis
and unanimously adopted the ‘‘Code of practice on the interna-
tional recruitment of health personnel,’’ whereby member states
committed themselves to the voluntary principles and practices
expressed therein for the ethical international recruitment of
health personnel. The code instituted an important governance
framework with principles that a number of countries are already
incorporating into national law and practice [23].
Information
This building block directly relates to cross-border supply of
services (WTO ‘‘mode 1’’) and encompasses the application of
information and communication technologies across the whole
range of functions that affect the health sector. This includes the
remote provision of a service from a provider in one country to an
overseas recipient; information provided through Web sites; an
increasingly wide range of telemedicine services; indirect ser-
vices, such as teleconferencing and teleeducation; and adminis-
trative functions (claims processing and medical transcriptions)
[10]. Telehealth based on mobile communications (m-health) is
growing fast and offers additional potential to transform health
services delivery across the globe [25]. Mobile technologies are
traded and made available in most remote areas worldwide, and
its use for diagnostic and training purposes can significantly
increase access to quality diagnostics and facilitate distant
training of local health workers [26].
However, access to medicines via globalization of the tradi-
tional media (such as TV) and the Internet has potential health
risks. TV channels in one country broadcast globally and often
include advertisements for legal prescription drugs that may be
illegal in other countries. Commercially sponsored disease
awareness campaigns might carry out a valuable public health
service, but often appear to be purely instrumental to increasing
product sales and part of a wider ‘‘disease mongering’’ strategy,
that is, the widening of the need for medical intervention by
distorting the prevalence and/or severity of a condition, redefin-
ing risk factors as diseases, inflating mild or self-limiting symp-
tomatic states, and pathologizing normal human variation.
Disease mongering increases not only sales but also demand
for services, putting an additional burden on health systems [27].
The Internet provides unparalleled opportunities not only for
direct legal drug sales but also for the trading of illegal drugs and
counterfeit medicines, with thousands of counterfeit incidents
per year. Information technologies and sales via online pharma-
cies have allowed the criminal element to thrive in an unregu-
lated environment of anonymity, deception, and lack of adequate
enforcement [28].
Medical Products
Diffusion of health technologies through global trade has
contributed greatly to worldwide health improvements. Fullydisclosed and carefully managed research collaborations between
academia and the pharmaceutical industry can be very valuable to
academic medical centers, industry, and the public and are likely to
improve public health through new discoveries [29]. Commercial
interests, however, may become pervasive and influence both
academic and international institutions [30].
Trade in medical products can also have negative conse-
quences with respect to equity in access [20]. The Trade Related
Intellectual Property Rights agreement has created a global
system of patent protection that may increase pharmaceutical
prices and reduce access to drugs and vaccines [31].
Remaining unaffordable to public health systems, the cost of
essential medicines may contribute to the trade of counterfeit drugs
in low-income countries—the most common destination [20].
Development of drugs does not correspond to the burden of
diseases but to the comparative commercial advantage: only 10%
of the US $55 billion global spending on health research is
devoted to conditions that account for 90% of the global burden
of disease [32]. Both research funding agencies and the corporate
sector in many industrialized countries link their priorities to the
anticipation of commercial returns; the result is a major mis-
match between health research priorities and the burden of
disease outside the industrialized world [16].
The push for pharmaceutical solutions to global health has
become predominant and problematic over the last decades. The
debate about ‘‘access’’ has been widely marked by the quest for
access to medicines and incentives for the pharmaceutical
industry to engage in the development of new drugs and vaccines
[33]. Market-based financing mechanisms have been launched
(such as the Advanced Market Commitment, the GAVI Alliance’s
International Financial Facility for Immunizations, or UNITAID’s
levy on airplane tickets) and narrowly targeted to develop and/or
buy drugs or vaccines [34], possibly rewarding companies with
prices much higher than needed when risks and costs of R&D to
develop medicines for global health problems are correctly
estimated [35].Financing
Foreign direct investment (WTO ‘‘mode 3’’) refers to the move-
ment of capital from one country to another, which most
commonly involves a joint venture between domestic and foreign
partners to establish new health services or purchase an existing
institution [10]. Especially in middle-income countries, commer-
cialization in the health care sector has been strongly influenced
by the entry of large health care corporations, and by foreign
private investment in provision and insurance, usually aiming at
reduced risk exposure and short-term profits [22]. The private
sector may contribute to extending UHC by mobilizing additional
funds from those able to afford private cover, but UHC is
negatively affected when the sector is permitted to entrench
inequalities by excluding people with poor health from insurance
cover [6]. Lack of funds to finance the health sector coupled with
the inefficient allocation and use of health resources is one of the
key obstacles to UHC. These may be exacerbated by privatization
and fragmentation of the health care system with information
and patient flows disjointed between the public and the private
health sectors [6].
In many low-income countries, health expenditure depends
significantly on foreign official and, increasingly, private aid. The
above-mentioned focus on medical products, rather than health
systems, has also diverted to the market (e.g., through the
Advanced Market Commitment) public aid resources that could
otherwise have been destined to support the development of a
whole-system public health approach to the delivery of essential
services at the country level [35].
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The regressive impact on service delivery of the market-oriented
health sector reform, mandated during the latter quarter of the
last century by international financial institutions as part of
structural adjustment conditionality, has already been noted.
During that period, the WHO adopted some of those market-
style reforms, dropping the focus on universalism and equity in
favor of World Bank’s notion of an ‘‘essential package’’ of care for
the poor, with private sector provision for those who can afford to
pay. According to a report of the Organization for Economic
Cooperation and Development, these policies come with a price
tag of complications, contradictions, and increased costs [36].
The predominance of market forces has influenced the
architecture of global health governance. A remarkable upsurge
of new private actors and transnational public-private partner-
ships prevail over traditional multilateral institutions, as in the
case of the WHO whose priorities and spending have been
further determined by overdependency on often highly condi-
tional contributions from governmental and single private
donors [37]. Complex relationships between new and old actors
pose challenges in terms of coordination, roles, and rules setting
[38]. Also, countries’ own health governance and priority setting
is strongly influenced by earmarking and conditionality and,
again, the focus on medical products drives funding allocations
regardless of countries’ health needs [39].
When it comes to pushing public health concerns into trade
regulation and international negotiations, effective leadership is
paramount. Unfortunately, in almost all countries, health policy
receives a low status compared with the status of the commercial
interest in the setting of trade policy. Businesses have privileged
access to policymakers, thus dominating the formulation of
negotiating positions, and exerting a heavy influence on the
global trade agenda at the WTO or in the context of bilateral
and regional free-trade agreements [40].Conclusions
Global trade liberalization interacts with national health systems,
often with adverse impacts in terms of promoting UHC. This
liberalization does have some potential positive effects on popu-
lation health: the accelerated pace of global interdependence and
interconnectedness, aided by innovation in communication
technologies, facilitates the diffusion of new knowledge and
technology, contributing to disease surveillance, treatment and
prevention, and more rapid scientific discovery. It also facilitates
the establishment of virtual communities of support, global
advocacy, and action networks [36].
As detailed here, global trade liberalization can also have
negative effects on health systems’ capacity to ensure UHC. On
the one side, trade can increase the burden of disease and cause
higher demand; on the other hand, it can interfere with the
interconnected functioning of health systems’ building blocks.
This is especially true in the current weakness, not to say
absence, of governance mechanisms to ensure adequate health
protection and promotion in international negotiations and
policymaking fora, which often lie outside the control of agencies
primarily responsible for public health.
Thus, for an effective implementation of UHC, health prio-
rities need to substantially influence those external policy instru-
ments. To do this, higher emphasis should be put on global
governance for health, rather than circumscribing the debate in
the traditional, and currently rather confused, sector domain of
‘‘Global Health Governance’’ [41]. This has two implications. First,
it confirms the need, more than ever, of a strengthened norma-
tive role of the WHO as advocated by Chen and Berlinguer [42] adecade ago. Global trade and marketing strategies driving the
global burden of chronic diseases require the WHO to coura-
geously lead the development of new ad-hoc regulatory frame-
works, on the model of the Framework Convention on Tobacco
Control.
Second, it requires the WHO to be more proactive and timely
in representing health interests in other fora, such as in trade or
environmental negotiations, both regionally and globally, with
the aim of assisting governments at the national level to include
health provisions in all sectors [40].
As the Framework Convention on Tobacco Control experience
has also shown, such a challenging repositioning of the WHO
could take advantage of strong alliances with civil society
organizations that defend the public interest and identify global
health as a common good. In turn, the establishment of consis-
tent ‘‘health-in-all-sectors’’ policy frameworks will facilitate the
contribution of civil society organizations in upholding public
health protections and mobilizing public opinion to regulate the
behavior of powerful states and corporate interests [40].Acknowledgments
Some concepts presented in this article were shared in the
planning phase by Timothy Evans to whom the author is grateful
for the contribution. Thanks go also to Andrew Harmer for his
kind support in reviewing the manuscript.
R E F E R E N C E S[1] World Health Organization. The World Health Report 2008: Primary
Health Care Now More Than Ever. Geneva: World Health Organization,
2008:1–148.
[2] Latko B, Tempor ~ao JG, Frenk J, et al. The growing movement for
universal health coverage. Lancet 2011;377:2161–3.
[3] Smith RD, Lee K, Drager N. Trade and health: an agenda for action.
Lancet 2009;373:768–73.
[4] Carrin G, James C, Evans D. Achieving Universal Health Coverage:
Developing the Health Financing System. Geneva: World Health
Organization, 2005.
[5] Blouin C, Chopra M, van der Hoeven R. Trade and social determinants
of health. Lancet 2009;373:502–7.
[6] Allottey P, Yasin S, Tang S, et al. Universal coverage in an era of
privatization: can we guarantee health for all? BMC Public Health
2012;12(Suppl. 1):S1.
[7] CSDH. Closing the Gap in a Generation. Geneva: World Health
Organization, 2008.
[8] De Savigny D, Adam T, ed. Systems Thinking for Health Systems
Strengthening. Geneva: World Health Organization; 2009.
[9] World Health Organization. Everybody’s Business Strengthening Health
Systems to Improve Health Outcomes. Geneva: World Health
Organization, 2007.
[10] WHO, WTO. WTO Agreements & Public Health. Geneva: World Trade
Organization/World Health Organization, 2002.
[11] Benatar SR, Gill S, Bakker I. Global health and the global economic
crisis. Am J Pub Health 2011;101:646–53.
[12] Cornia GA. An empirical investigation of the relation between
globalization and health. In: Labonte´ R, ed. Globalization and Health:
Pathways, Evidence and Policy. London: Routdledge; 2009.
[13] Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic:
shaped by global drivers and local environments. Lancet
2011;378:804–14.
[14] Huynen MM, Martens P, Hilderink HB. The health impacts of
gobalization: a conceptual framework. Global Health 2005;1:14.
[15] Labonte´ R, Schrecker T. Globalization and social determinants of
health: the role of the global marketplace (part 2 of 3). Global Health
2007;3:6.
[16] Munasinghe M. Millennium Consumption Goals (MCGs) for Rioþ 20
and beyond: a practical step towards global sustainability. Nat Res
Forum 2012;36:202–12.
[17] Skinner MK, Manikkam M, Guerrero-Bosagna C. Epigenetic
transgenerational actions of environmental factors in disease etiology.
Trends Endocrinol Metab 2010;21:214–22.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) S 1 4 – S 1 8S18[18] Friel S, Campbell-Lendrum D, Frumkin H, et al. Climate change,
noncommunicable diseases, and development: the relationships and
common policy opportunities. Ann Rev Pub Health 2011;32:133–47.
[19] Fidler DP, Drager N, Lee K. Managing the pursuit of health and wealth:
the key challenges. Lancet 2009;373:325–31.
[20] Labonte´ R. Global Health Policy: Exploring the Rationale for Health in
Foreign Policy. Ottawa, Canada: Globalization and Health Equity
Institute, Population Health University of Ottawa, 2010:1–108.
[21] Chopra M, Darnton-Hill I. Tobacco and obesity epidemics: not so
different after all? BMJ 2004;328:1–3.
[22] United Nations Research Institute for Social Development.
Commercialization and Globalization of Health Care: Lessons from
UNRISD Research (United Nations Research Institute for Social
Development Research and Policy Brief 7). Geneva: United Nations
Research Institute for Social Development, 2007:4.
[23] Taylor AL, Hwenda L, Larsen B-I, Daulaire N. Stemming the brain drain
– a WHO global code of practice on international recruitment of health
personnel. N Engl J Med 2011;365(25):2348–51.
[24] Smith RD, Chanda R, Tangcharoensathien V. Trade in health-related
services. Lancet 2009;373:593–601.
[25] World Health Organization. MHealth: New Horizons for Health
Through Mobile Technologies (Vol. 3, Global Observatory for eHealth
Series). Geneva: World Health Organization, 2011:1–112.
[26] Bellina L, Missoni E. M-learning: mobile phones’ appropriateness and
potential for the training of laboratory technicians in limited-resource
settings. Health Technol 2011;8:1–5.
[27] Doran E, Henry D. Disease mongering: expanding the boundaries of
treatable disease. Intern Med J 2008;38:858–61.
[28] Mackey TK, Liang BA. The global counterfeit drug trade: patient safety
and public health risks. J Pharm Sci 2011;100:4571–9.
[29] Johnston SC, Hauser SL, Desmond-Hellmann S. Enhancing ties
between academia and industry to improve health. Nat Med
2011;17:434–6.[30] Mullard A.WHO report on drug development marred by big pharma
leak. Nat Med 2010;16:133.
[31] Smith RD, Correa C, Oh C. Trade TRIPS. and pharmaceuticals. Lancet
2009;373:684–91.
[32] Global Forum for Health Research. The 10/90 Report on Health
Research 2003–2004. Geneva: Global Forum for Health Research, 2004.
[33] McGoey L, Reiss J, Wahlberg A. The global health complex. BioSocieties
2011;6:1–9.
[34] McCoy D, Brikci N. Taskforce on innovative international financing
for health systems: what next? Bull World Health Organ
2010;88:478–80.
[35] Light DW, Warburton R. Demythologizing the high costs of
pharmaceutical research. BioSocieties 2011;6:34–50.
[36] Lister J. Globalization and Health Systems Change. Ottawa:
Globalization and Health Knowledge Network Research Papers
2008:1–104.
[37] Hawkes N. ‘‘Irrelevant’’ WHO outpaced by younger rivals. BMJ
2011;343:d5012.
[38] Szleza´k NA, Bloom BR, Jamison DT, et al. The global health system:
actors, norms, and expectations in transition. PLoS Med
2010;7:e1000183.
[39] Biesma RG, Brugha R, Harmer A, et al. The effects of global health
initiatives on country health systems: a review of the evidence from
HIV/AIDS control. Health Pol Plan 2009;24:239–52.
[40] Lee K, Sridhar D, Patel M. Bridging the divide: global governance of
trade and health. Lancet 2009;373:416–22.
[41] Faid M. Tackling Cross-Sectoral Challenges to Advance Health as Part of
Foreign Policy. Oslo: Fridtjof Nansen Institute, 2012.
[42] Chen LC, Berlinguer G. Health equity in a globalizing world. In: Evans T,
Whitehead M, Finn D, eds. Challenging Inequities in Health:
From Ethics to Action. (1st ed.). New York: Oxford University Press;
2001.
